GVK Bio, Wyeth sign drug discovery pact
GVK Bio has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to undertake drug discovery research and generate intellectual property (IP). Based on the research output, the company would file INDs (Investigative New Drug) with the US Food & Drug Administration. The work would be largely on drug candidates focused on pre-defined discovery targets. GVK Bio, the Hyderabad-based company, will utilise in-house capabilities in discovery chemistry, informatics, biology and toxicology to advance this collaborative programme expected to be between 2-3 years.